Patents by Inventor Marie-Gabrielle Braun

Marie-Gabrielle Braun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11760753
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: September 19, 2023
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
  • Publication number: 20230057166
    Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: September 12, 2019
    Publication date: February 23, 2023
    Inventors: Marie-Gabrielle Braun, Cuong Q. Ly, Georgette Castanedo, Paul Gibbons, Wendy Lee, Joachim Rudolph, Nicole Alice Blaquiere, Jacob Bradley Schwarz, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Leo Fu
  • Publication number: 20230047209
    Abstract: Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods treating cancer, alone and in combination with other therapeutic agents.
    Type: Application
    Filed: July 2, 2021
    Publication date: February 16, 2023
    Inventors: Marie-Gabrielle Braun, Georgette Castanedo, Paul Gibbons, Joachim Rudolph, William Vernier, Ramsay Beveridge, Yao Wu, Guosheng Wu
  • Publication number: 20230025834
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 26, 2023
    Applicant: Genentech, Inc.
    Inventors: Guosheng WU, Emily J. HANAN, Marie-Gabrielle BRAUN, Sharada S. LABADIE, Keira GARLAND, Richard M. PASTOR, Paul Anthony GIBBONS, Yuhong FU, Yun-Xing CHENG
  • Publication number: 20220249487
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.
    Type: Application
    Filed: December 10, 2021
    Publication date: August 11, 2022
    Inventors: Marie-Gabrielle Braun, Georgette Castanedo, Paul Gibbons, Joachim Rudolph, Yao Wu, Guosheng Wu
  • Publication number: 20220204498
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.
    Type: Application
    Filed: August 17, 2021
    Publication date: June 30, 2022
    Inventors: Marie-Gabrielle Braun, Joachim Rudolph, Yao Wu, Guosheng Wu
  • Patent number: 11279735
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: March 22, 2022
    Assignee: Genentech, Inc.
    Inventors: Emily J. Hanan, Georgette Castanedo, Marie Gabrielle Braun, Keira Garland, Peter Andrew Smith, Richard Pastor, Paul Gibbons, Yunxing Cheng, Guosheng Wu, Yuhong Fu, Po-Wai Yuen
  • Publication number: 20220048888
    Abstract: Described herein are phenoxy-pyridazinyl-pyrimidine or phenoxy-pyrimidinyl-pyrimidine compounds and pharmaceutically acceptable salts thereof for use in the treatment of Ire1-mediated diseases and cancer.
    Type: Application
    Filed: September 11, 2019
    Publication date: February 17, 2022
    Inventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Q. Ly, Joachim Rudolph, Jacob Bradley Schwarz, Avi Ashkenazi, Ramsay Beveridge, Liang Zhao, Alexandre Lemire, Leo Fu, Kwong Wah Lai, Fei Wang
  • Publication number: 20210246129
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Application
    Filed: October 20, 2020
    Publication date: August 12, 2021
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle BRAUN, Emily HANAN, Steven T. STABEN, Robert Andrew HEALD, Calum MACLEOD, Richard ELLIOTT
  • Patent number: 10968203
    Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I? structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I? compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 6, 2021
    Assignees: Genentech, Inc., The Regents of the University of California
    Inventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Ly, Joachim Rudolph, Jacob Schwarz, Avi Ashkenazi, Leo Fu, Tommy Lai, Fei Wang, Ramsay Beveridge, Liang Zhao
  • Patent number: 10851091
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: December 1, 2020
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum Macleod, Richard Elliott
  • Publication number: 20200331968
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Application
    Filed: March 12, 2020
    Publication date: October 22, 2020
    Applicant: Genentech, Inc.
    Inventors: Emily J. HANAN, Georgette CASTANEDO, Marie Gabrielle BRAUN, Keira GARLAND, Peter Andrew SMITH, Richard PASTOR, Paul GIBBONS, Yunxing CHENG, Guosheng WU, Yuhong FU, Po-Wai YUEN
  • Patent number: 10435414
    Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: October 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
  • Publication number: 20190263793
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Application
    Filed: September 24, 2018
    Publication date: August 29, 2019
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle BRAUN, Emily HANAN, Steven T. STABEN, Robert Andrew HEALD, Calum MACLEOD, Richard ELLIOTT
  • Publication number: 20180327420
    Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Application
    Filed: July 25, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
  • Patent number: 10112932
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation. Also described are methods of making the benzoxazepin oxazolidinone compounds having the Formula I structure.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: October 30, 2018
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
  • Publication number: 20180265497
    Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I? structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I? compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Applicants: Genentech, Inc., The Regents of the University of California
    Inventors: Marie-Gabrielle Braun, Paul Gibbons, Wendy Lee, Cuong Ly, Joachim Rudolph, Jacob Schwarz, Avi Ashkenazi, Leo Fu, Tommy Lai, Fei Wang, Ramsay Beveridge, Liang Zhao
  • Patent number: 10065970
    Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: September 4, 2018
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
  • Publication number: 20180162873
    Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Application
    Filed: September 7, 2016
    Publication date: June 14, 2018
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
  • Publication number: 20180127404
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation. Also described are methods of making the benzoxazepin oxazolidinone compounds having the Formula I structure.
    Type: Application
    Filed: October 10, 2017
    Publication date: May 10, 2018
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott